Potential and caveats of TRAIL in cancer therapy

Drug Resistance Updates

Volumn 4, Issue 4, 2001, Pages 243-252

  Held, Jürgen ^a   Schulze Osthoff, Klaus ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

6 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 2 NAPHTHOIC ACID; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; CYCLOHEXIMIDE; CYTARABINE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; PACLITAXEL; PROTEASOME INHIBITOR; RETINOID DERIVATIVE; STAUROSPORINE; TOPOTECAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; DRUG SENSITIZATION; GENE EXPRESSION; HUMAN; IONIZING RADIATION; LIVER TOXICITY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

EID: 0035735753     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.2001.0208     Document Type: Review

References (116)

1. Apoptosis in the pathogenesis and treatment of disease
2. Caspases: Killer proteases
3. The role of caspases in development, immunity, and apoptotic signal transduction: Lessons from knockout mice
4. Death by a thousand cuts: An ever increasing list of caspase substrates
5. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor
6. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex
7. Apoptosis signaling by death receptors
8. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade
9. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis
10. Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction
11. Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis
12. Identification and characterization of a new member of the TNF family that induces apoptosis
13. Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA
14. Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL
15. Triggering cell death: The crystal structure of Apo2L/TRAIL in a complex with death receptor 5
16. A unique zinc-binding site revealed by a high-resolution x-ray structure of homotrimeric Apo2L/TRAIL
17. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells
18. Interleukin I beta-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells
19. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors
20. The receptor for the cytotoxic ligand TRAIL
21. TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL
22. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain
23. An antagonist decoy receptor and a death domain-containing receptor for TRAIL
24. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family
25. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL
26. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma
27. In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-kappa B activity
28. Functional analysis of TRAIL receptors using monoclonal antibodies
29. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes
30. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5
31. Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells
32. TRAIL receptor-2 signals apoptosis through FADD and caspase-8
33. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5
34. FADD/MORTI and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2
35. Signaling events triggered by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): Caspase-8 is required for TRAIL-induced apoptosis
36. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells
37. Inherited human caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II
38. Intracellular mechanisms of TRAIL: Apoptosis through mitochondrial-dependent and -independent pathways
39. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway
40. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB
41. Dominant-negative FADD inhibits TNFR60-, Fas/Apo1- and TRAIL-R/Apo2-mediated cell death but not gene induction
42. FADD: Essential for embryo development and signaling from some, but not all, inducers of apoptosis
43. FADD is required for DR4- and DR5-mediated apoptosis: Lack of TRAIL-induced apoptosis in FADD-deficient mous embryonic fibroblasts
44. A GTP-binding adapter protein couples TRAIL receptors to apoptosis-inducing proteins
45. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression
46. TRAIL (Apo2 ligand) and TWEAK (Apo3 ligand) mediate CD4+ T cell killing of antigen-presenting macrophages
47. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
48. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems
49. Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells
50. TRAIL/Apo-2-ligand-induced apoptosis in human T cells
51. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL
52. IFN-gamma mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression
53. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs
54. Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells
55. Surface expression of TRAIL/Apo-2 ligand in activated mouse T and B cells
56. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
57. Natural killer (NK) cell-mediated cytotoxicity: Differential use of TRAIL and Fas ligand by immature and mature primary human NK cells
58. The involvement of TNF-alpha-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-beta-stimulated human dendritic cells to tumor cells
59. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis
60. Theiler's murine encephalomyelitis virus induces apoptosis in gamma interferon-activated M1 differentiated myelomonocytic cells through a mechanism involving tumor necrosis factor alpha (TNF-alpha) and TNF-alpha-related apoptosis-inducing ligand
61. Identification of a potential HIV-induced source of bystander-mediated apoptosis in T cells: Upregulation of TRAIL in primary human macrophages by HIV-1 Tat
62. D nucleotide substitution in the ectodomain of TRAIL receptor DR4 is associated with lung cancer and head and neck cancer
63. Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma
64. Death domain mutagenesis of killer/dr5 reveals residues critical for apoptotic signaling
65. TRAIL-R2 is not correlated with p53 status and is rarely mutated in non-small cell lung cancer
66. Chromosomal imbalances associated with response to chemotherapy and cytotoxic cytokines in human malignant glioma cell lines
67. Three adenovirus E3 proteins cooperate to evade apoptosis by tumor necrosis factor-related apoptosis-inducing ligand receptor-1 and -2
68. Sensitization of human colon cancer cells to TRAIL-mediated apoptosis
69. Maturation of dendritic cells leads to up-regulation of cellular FLICE-inhibitory protein and concomitant down-regulation of death ligand-mediated apoptosis
70. NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling
71. The role of NF-kappaB: In TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells
72. Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells
73. The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract
74. The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase
75. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis
76. Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells
77. Activation of protein kinase C inhibits TRAIL-induced caspases activation, mitochondrial events and apoptosis in a human leukemic T cell line
78. Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells
79. Pretreatment with paclitaxel enhances Apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels
80. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo
81. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL
82. Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by selective up-regulation of TRAIL-R1
83. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha
84. Sensitization of AIDS-Kaposi's sarcoma cells to Apo-2 ligand-induced apoptosis by actinomycin D
85. Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL
86. Synergistic cytotoxicity and apoptosis by Apo-2 ligand and adriamycin against bladder cancer cells
87. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines
88. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis
89. Sodium nitroprusside enhances TRAIL-induced apoptosis via a mitochondria-dependent pathway in human colorectal carcinoma CX-1 cells
90. Apoptotic responsiveness of the Ewing's sarcoma family of tumours to tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)
91. Induction of apoptosis in glioma cell lines by TRAIL/Apo-21
92. Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines
93. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells
94. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: The trail to non-toxic cancer therapeutics
95. Synergistic induction of apoptosis by the combination of TRAIL and chemotherapy in chemoresistant ovarian cancer cells
96. Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells
97. Augmented pro-apoptotic effects of TRAIL and proteasome inhibitor in human promonocytic leukemic U937 cells
98. Implication of multiple mechanisms in apoptosis induced by the synthetic retinoid CD437 in human prostate carcinoma cells
99. Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan
100. TRAIL-induced apoptosis of thyroid cancer cells: Potential for therapeutic intervention
101. Taxol induces Bcl-2 phosphorylation and death of prostate cancer cells
102. Interferon gamma induces upregulation and activation of caspases 1, 3, and 8 to produce apoptosis in human erythroid progenitor cells
103. Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis
104. Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression
105. Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression
106. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
107. Safety and antitumor activity of recombinant soluble Apo2 ligand
108. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene
109. Global effects of anchorage on gene expression during mammary carcinoma cell growth reveal role of tumor necrosis factor-related apoptosis-inducing ligand in anoikis
110. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells
111. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL
112. The TRAIL to an anti-cancer agent
113. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand
114. Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL)
115. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
116. Avoiding premature apoptosis of normal epidermal cells